Literature DB >> 361576

Association of elevated levels of extracellular neuraminidase with clinical isolates of type III group B streptococci.

T W Milligan, C J Baker, D C Straus, S J Mattingly.   

Abstract

The level of total extracellular neuraminidase produced by 74 clinical isolates of group B streptococci isolated from diseased or asymptomatically colonized infants was assayed. Extracellular neuraminidase was obtained from concentrated filtrates of exponentially growing cultures of group B streptococci grown in a chemically defined medium (FMC) containing supplemental protein. The total activity of extracellular enzyme produced by these clinical isolates ranged from less than 10 to 360 nmol of sialic acid released per min per mg of cell dry weight. Strains were arbitrarily classified as either nonproducers (less than 10 nmol/min per mg of cell dry weight), low producers (greater than 10 to less than or equal 140 nmol/min per mg of cell dry weight), or high producers (greater than 140 to 360 nmol/min per mg of cell dry weight). Type III isolates from diseased infants were significantly more often classified as high producers than strains of group B streptococci of other serotypes from diseased infants (P less than 0.001). Furthermore, the serotype III strains isolated from neonatal infections were more often high producers than those of the same serotype from asymptomatically colonized infants (P less than 0.025). These results suggest that the ability to produce elevated levels of neuraminidase may be related to the frequent association of type III strains with disease among neonates.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 361576      PMCID: PMC422060          DOI: 10.1128/iai.21.3.738-746.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids.

Authors:  D AMINOFF
Journal:  Biochem J       Date:  1961-11       Impact factor: 3.857

2.  Correlation between composition, structure, shape and function of a salivary mucoprotein.

Authors:  A GOTTSCHALK
Journal:  Nature       Date:  1960-06-18       Impact factor: 49.962

3.  Role of sialic acid in survival of erythrocytes in the circulation: interaction of neuraminidase-treated and untreated erythrocytes with spleen and liver at the cellular level.

Authors:  D Aminoff; W F Bruegge; W C Bell; K Sarpolis; R Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

4.  Growth and amino acid requirements of various strains of group B streptococci.

Authors:  T W Milligan; T I Doran; D C Straus; S J Mattingly
Journal:  J Clin Microbiol       Date:  1978-01       Impact factor: 5.948

Review 5.  The emergence of group B streptococci in infections of the newborn infant.

Authors:  B F Anthony; D M Okada
Journal:  Annu Rev Med       Date:  1977       Impact factor: 13.739

6.  Group B streptococcal infections in infants. The importance of the various serotypes.

Authors:  C J Baker; F F Barrett
Journal:  JAMA       Date:  1974-11-25       Impact factor: 56.272

7.  Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis.

Authors:  J B Robbins; G H McCracken; E C Gotschlich; F Orskov; I Orskov; L A Hanson
Journal:  N Engl J Med       Date:  1974-05-30       Impact factor: 91.245

8.  Analysis of group B streptococcal types associated with disease in human infants and adults.

Authors:  H W Wilkinson
Journal:  J Clin Microbiol       Date:  1978-02       Impact factor: 5.948

9.  Extracellular neuraminidase production by group B streptococci.

Authors:  T W Milligan; D C Straus; S J Mattingly
Journal:  Infect Immun       Date:  1977-10       Impact factor: 3.441

10.  Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus.

Authors:  C J Baker; D L Kasper; A Paredes; S Alpert; W M McCormack; D Goroff
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  34 in total

1.  Deposition and degradation of C3 on type III group B streptococci.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

2.  High-virulence clone of group B streptococci unable to grow at high temperatures is present in serotypes other than type III.

Authors:  Gerardo C Palacios; Maria N Gonzalez; Magdalena Beltran; Jose L Arredondo; Javier Torres; Fortino Solorzano
Journal:  Curr Microbiol       Date:  2006-12-13       Impact factor: 2.188

3.  Opsonization of group B Streptococcus type III: studies using clinical strains and maternal sera.

Authors:  M J Hastings; J Neil; C S Easmon
Journal:  Br J Exp Pathol       Date:  1985-06

4.  Association of type- and group-specific antigens with the cell wall of serotype III group B streptococcus.

Authors:  T I Doran; S J Mattingly
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

5.  Type-specific capsular antigen is associated with virulence in late-onset group B Streptococcal type III disease.

Authors:  M E Klegerman; K M Boyer; C K Papierniak; L Levine; S P Gotoff
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

6.  Neuraminidase activity of Pasteurella haemolytica isolates.

Authors:  G H Frank; L B Tabatabai
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

7.  Population structure of Streptococcus agalactiae reveals an association between specific evolutionary lineages and putative virulence factors but not disease.

Authors:  M Hauge; C Jespersgaard; K Poulsen; M Kilian
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

8.  Characterization of neuraminidases produced by various serotypes of group B streptococci.

Authors:  J G Brown; D C Straus
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

9.  Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal disease.

Authors:  J M Musser; S J Mattingly; R Quentin; A Goudeau; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

10.  Group B Streptococcus Evades Host Immunity by Degrading Hyaluronan.

Authors:  Stacey L Kolar; Pierre Kyme; Ching Wen Tseng; Antoine Soliman; Amber Kaplan; Jiurong Liang; Victor Nizet; Dianhua Jiang; Ramachandran Murali; Moshe Arditi; David M Underhill; George Y Liu
Journal:  Cell Host Microbe       Date:  2015-12-09       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.